SNN:NYE-Smith & Nephew SNATS Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 30.71

Change

-0.25 (-0.81)%

Market Cap

USD 13.74B

Volume

0.88M

Analyst Target

USD 45.30
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-3.25 (-2.75%)

USD 199.88B
MDT Medtronic PLC

-0.50 (-0.56%)

USD 115.58B
STE STERIS plc

-3.30 (-1.37%)

USD 24.14B
ZBH Zimmer Biomet Holdings Inc

+0.04 (+0.04%)

USD 21.64B
BIO Bio-Rad Laboratories Inc

+6.79 (+2.04%)

USD 9.45B
GMED Globus Medical

+0.25 (+0.36%)

USD 9.39B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.26B
PEN Penumbra Inc

+8.52 (+4.55%)

USD 7.77B
GKOS Glaukos Corp

+0.73 (+0.60%)

USD 6.94B
INSP Inspire Medical Systems Inc

+1.69 (+0.82%)

USD 6.08B

ETFs Containing SNN

CIB0:XETRA VanEck Bionic Engineering.. 3.84 % 0.00 %

-0.29 (-1.52%)

USD 6.36M
DTEC ALPS Disruptive Technolog.. 1.32 % 0.00 %

-0.19 (-1.52%)

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.57% 68% D+ 68% D+
Dividend Return 1.69% 100% F 38% F
Total Return 14.27% 68% D+ 66% D+
Trailing 12 Months  
Capital Gain 19.03% 65% D 65% D
Dividend Return 2.91% 89% A- 44% F
Total Return 21.94% 68% D+ 64% D
Trailing 5 Years  
Capital Gain -35.71% 22% F 14% F
Dividend Return 7.85% 80% B- 25% F
Total Return -27.86% 30% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -10.83% 21% F 7% C-
Dividend Return -8.69% 24% F 7% C-
Total Return 2.14% 88% B+ 46% F
Risk Return Profile  
Volatility (Standard Deviation) 15.59% 100% F 63% D
Risk Adjusted Return -55.76% 18% F 5% F
Market Capitalization 13.74B 86% B+ 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.